Lably
Skip to content

Cristina Alberini

Italian neuroscientist

  • 3 min read
  • 2 chapters

Related on Lably

Through Long-term memory, Recall (memory) and Amnesia

Her research focuses on understanding the cellular and molecular mechanisms underlying the stabilization, storage, and consolidation of long-term memories. Another part of her research involved the study of memory retrieval and reconsolidation.

In 2017 she was elected to the Dana Alliance for Brain Initiatives and awarded the Lombardy Region Rosa Camuna Award in 2019. In 2022 she was appointed as a Member of the American Academy of Arts and Sciences.

Biography

She studied biology and graduated with honors from the University of Pavia, in Italy. Her undergraduate research focused in the study of antibodies in vitro. She obtained a doctoral degree in immunological sciences from the University of Genoa, where she studied T-cell antigen receptors.

In 1985 she got a post-doctoral research fellowship to work in the Dana–Farber Cancer Institute at Harvard Medical School. Later she obtained a second post-doctoral fellowship to work at Columbia University working in the laboratory of Eric Kandel from 1991 to 1994 where she trained as a neurobiologist. During this time, her research focused in studying the role of gene expression regulation during long-term synaptic plasticity.

In 1997 Cristina joined Brown University as an assistant professor of neuroscience. Years later, in 2001, she moved to the Icahn School of Medicine at Mount Sinai, where she acted as an assistant professor until 2010 when she was promoted to full professor. In 2011 she joined the Center for Neural Science at the New York University as a full professor in neuroscience.

Starting in 2002, she trained as a psychoanalyst at National Association for the Advancement of Psychoanalysis (NPAP) in New York, and became licensed in the same state in 2012. Since then, she became actively involved in the merging of neuroscience and psychoanalysis to promote a comprehensive and multidisciplinary approach to study brain and mind, as well as to facilitate the development of scientifically based psychotherapeutic approaches.

She founded the biotech company Ritrova Therapeutics Inc. in 2020 with the aim of exploring new treatments for neurodegenerative diseases and neurodevelopmental disorders by targeting novel mechanisms of brain protein metabolism regulation.

Sign in to keep reading

One more chapter is free with a Lably account.

More in Neuroscience